Abstract:ID 96214 Poster Board 484 Statement of the Problem . Epilepsy is the 4 th common neurological disorder after Parkinson's and Alzheimer's Disease and Stroke, with 3 million people in the US and 65 million people worldwide living with epilepsy. At the molecular level, it is known that voltage-gated sodium (VGSC) and calcium channels are related to the onset of seizures. Our lab engages in early drug design and discovery of novel small molecules as potential anti-seizure analogs, for epilepsy. Previous hit-to-lead optimization and target identification studies performed by our research team, led to the discovery of lead compound, ETSP 518001.This analog has been shown to act as a potent and selective Ca v 3.2 and Ca v 3.3 T-type voltage-gated calcium channel (T-VGCC) inhibitor. The objective of the work presented is to evaluate the inhibitory effects of several novel enaminone derivatives based on the prototype ETSP 518001 to identify new lead compounds as T-VGCC inhibitors. Methods: To design the novel enaminone derivatives, we utilized MedChem Studio, a simulation program to determine the druggability of the desired small molecules. Preliminary in vitro whole cell patch clamp experiments were performed to assess the inhibitory effects of several target analogs on voltage-activated Ca 2+ currents in human embryonic kidney (HEK-293) cells. Cav3.2 transfected HEK 293 cells were treated with 50 μM of test compounds and compared to the control group (none pretreated HEK 293 cells). Statistical analyses consisted of t-test for pairwise comparisons or one-way ANOVA followed by post hoc analysis using Tukey's honest significant difference test for comparisons between multiple groups. To validate the biological activity, studies were conducted at the National Institutes of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, NIH. ETSP 578001 was investigated in acute rodent seizure models, to determine the efficacy and safety as an anti-seizure agent. Results. Each enaminone analog in our novel series were examined in MedChem studio and were calculated to have an average CLogP value of 2.96, and predicted to have high blood brain barrier permeability (99%). Preliminary in vitro studies showed ETSP 578001 has ≥ 90% inhibition of T-VGCC current, generated by the Ca v 3.2 subunit. Enaminone analog RHB62 caused a reduction in the Ca 2+ current, with lower potency than ETSP 578001. No inhibitory effect was shown at a similar concentration for analogs RHB59, RHB95 or RHB103. Further research showed that ETSP 578001 analog also inhibited VGSCs and had no effect on cell viability. These results show that ETSP 578001 had dual inhibition properties. Results from the preclinical in vivo study demonstrated that compound ETSP 587001 had low efficacy in the 6Hz 44 mA and the maximal electroshock (MES) rodent seizure model, as 0/4 animals were protected at pretreatment times 0.5h and 2h. Conclusion: A target-based drug design strategy was employed, that led to the discovery of ETSP 578001, as a dual VGSC and T-VGCC blocker. This analog showed toxicity in the ETSP rodent seizure model. Future studies will involve lead optimization and target identification studies on ETSP 578001. PhRMA Foundation, Pre-Doctoral Fellowship in Drug Discovvery University of Maryland Eastern Shore Richard A. Bernstein Endowment

Sustained Inhibition of GABA-AT by OV329 Enhances Neuronal Inhibition and Prevents Development of Benzodiazepine Refractory Seizures

Effect of diazoxide on regulation of vesicular and plasma membrane GABA transporter genes and proteins in hippocampus of rats subjected to picrotoxin-induced kindling.

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System

Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats

Early vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus

In vivo biomarkers of GABAergic function in epileptic rats treated with the GAT‐1 inhibitor E2730

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development

A sensitive period of mice inhibitory system to neonatal GABA enhancement by vigabatrin is brain region dependent

Synthesis of 1,3,4-oxadiazole derivatives with anticonvulsant activity and their binding to the GABAA receptor

Ω-Conotoxin MVIIA Inhibits Amygdaloid Kindled Seizures in Sprague–Dawley Rats

Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medication

Effects of the Calcium Channel Blocker Otilonium Bromide on Seizure Activity in Rats With Pentylenetetrazole-Induced Convulsions

Enhancing GABAergic Tonic Inhibition Reduces Seizure-Like Activity in the Neonatal Mouse Hippocampus and Neocortex

SEW2871 reduces seizures via the sphingosine 1‐phosphate receptor‐1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug‐refractory epilepsy

The Effect of Pyridine Oxime Derivative (GIZh-298) and Sodium Valproate on the Neurotransmitter Amino Acids Content in the Brain Structures of Mice in the Maximal Electroshock Seizure Test

Treatment of Epilepsy: the Gaba-Transaminase Inhibitor, Vigabatrin, Induces Neuronal Plasticity in the Mouse Retina

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

Development of new chiral 1,2,4-triazole-3-thiones and 1,3,4-thiadiazoles with promising in vivo anticonvulsant activity targeting GABAergic system and voltage-gated sodium channels (VGSCs)

Anti-seizure effects of JNJ-54175446 in the intra-amygdala kainic acid model of drug-resistant temporal lobe epilepsy in mice

Disrupting Epileptiform Activity by Preventing Parvalbumin Interneuron Depolarization Block

Absence epileptic activity changing effects of non-adenosine nucleoside inosine, guanosine and uridine in Wistar Albino Glaxo Rijswijk rats